Oceana Therapeutics has signed a definitive agreement for the sale of its operating subsidiary to Salix Pharmaceuticals for $300m.

Oceana Business Development executive vice-president Gregory Stokes said the sale is expected to benefit both companies, as well as physicians and patients, through the integration of Oceana’s commercial assets, Deflux and Solesta, with Salix’s gastroenterology treatments.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The US Food and Drug Administration (FDA) approved and CE marked Deflux is intended for the treatment of vesicoureteral reflux, an anatomical bladder defect afflicting children.

Solesta, a biocompatible tissue bulking agent, is used as a non-surgical treatment for fecal incontinence.

The transaction is expected to close by the end of 2011, subject to routine closing conditions, including Hart-Scott-Rodino antitrust approval.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now